We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite announcing positive results for its phase 2/3 COVID-19 antibody cocktail trial Thursday, a potential safety signal has led Regeneron to temporarily stop enrolling patients who require high-flow oxygen or mechanical ventilation. Read More
The researchers hope to determine whether the drug improves blood oxygen levels and reduces mortality as well as time spent in an intensive care unit. Read More
The international medical aid group Doctors Without Borders has called on Sanofi and GlaxoSmithKline (GSK) to make their COVID-19 vaccine available at cost once approved. Read More
Data from Regeneron’s phase 2/3 trial of its COVID-19 antibody cocktail showed the treatment significantly reduced viral load and the number of medical visits needed by nonhospitalized patients, the company said Thursday. Read More
Moderna is still on track to file for Emergency Use Authorization (EUA) for its COVID-19 vaccine in the later part of November and is currently gearing up for worldwide distribution. Read More
The U.S. government has struck a $375 million deal with Eli Lilly for 300,000 vials of its investigational COVID-19 treatment, LY-CoV555 (bamlanivimab). Read More
The Center for Biologics Evaluation and Research (CBER) plans to issue guidance that details manufacturing considerations for approved and investigational cellular and gene therapy products during the COVID-19 pandemic. Read More
Sanofi and GlaxoSmithKline (GSK) have signed an agreement with Gavi, the Vaccine Alliance pledging to provide 200 million doses of their COVID-19 vaccine to the COVAX initiative should the vaccine clear regulatory hurdles. Read More